High population immunity from widespread prior infections and updated vaccines has kept severe outcomes low, supporting trader consensus that a new COVID variant of concern is unlikely before 2027. Current subvariants such as XFG, NB.1.8.1, and BA.3.2 circulate with notable spike mutations, yet health agencies report no elevation to variant-of-concern status and assess public health risk as low due to limited evidence of increased transmissibility, immune escape, or hospitalization rates. Ongoing genomic surveillance through wastewater and traveler programs shows these lineages co-circulating at modest levels without rapid dominance or clinical impact, while seasonal patterns and compensatory mutation barriers further constrain major shifts in the near term.